Synaptogenix Inc (SNPX)

[SF Wolf]

Your logic is faulty. The part you are leaving out is that of the
150,000,000 shares authorized none have been sold or issued. It appears that NTRP will raise money after the Ph2b results are released not before.

If the Aegis report was a true pump job Neurotrope would already be in the market with an offering before results, that is just not the case.

The company has no debt, approximately $20 million in the bank, $50 plus million in outstanding warrants and options when exercised, and now, once results are out, the opportunity to raise additional funds at a much higher market cap. That will give them leverage when they negotiate with a Big Pharma suitor or they can pursue there own Ph3 and Ph2b open label follow-on studies .

Neurotrope has made all of the right moves.